DOCSLIB.ORG

Strategic Plan V3 CXNS

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Strategic Plan V3 CXNS Acknowledgments The North Carolina Biotechnology Center thanks the Golden LEAF (Long-term Economic Advancement Foundation) for providing a grant to support the development of this strategic plan. The Biotechnology Center also acknowl- edges the important contributions of RTS Inc., which facilitated work group meetings and participated in the development of strategic recommendations, and Duke Power for contributing to the printing costs of this document. Also essential to the development of this plan were the participation and contributions of the following Biotechnology Center staff: Leslie Alexandre Nancy Kozlowski Christy Russell Steven Burke Sperry Krueger Bill Schy John Craichy Rob Lindberg Barry Teater Boris Hartl Robert Peterson Ken Tindall Kathleen Kennedy Maria Rapoza Amanda Wherry New Jobs Across North Carolina Message from the Governor Economic development in North Carolina has always been guided by three core beliefs: progress, education, and innovation. Our state’s biotechnology industry has been built on these beliefs. Today it is an essential economic engine that can benefit all North Carolinians. North Carolina’s biotechnology industry ranks among the nation’s five larg- est, with more than companies employing , people and generating annual revenues of billion. Despite the economic downturn, this industry is growing to percent a year. Our universities are discovering and devel- oping new technologies, new companies are being created, established com- panies are expanding, and companies are moving new products toward the market. Although we have had much success, I believe that we have only scratched the surface of North Carolina’s potential in biotechnology. To reach that potential, we need a clear roadmap to the state’s biotechnology future — a plan that fully taps North Carolina’s many resources to create jobs and products for today and the future. With this imperative in mind, last summer I asked former governors Jim Hunt and Jim Martin to chair a blue ribbon steering committee charged with devel- oping a strategic plan for maintaining and improving North Carolina’s strong position in biotechnology. For the past six months, with able support from the North Carolina Biotechnology Center, the best and brightest scientists, edu- cators, business and government leaders, university and community college leaders, economic developers, and biotechnology experts from every corner of North Carolina have been working hard to develop this plan. is report, New Jobs Across North Carolina: A Strategic Plan for Growing the Economy Statewide through Biotechnology, is the culmination of that effort. It includes recommendations on how we can attract and grow new companies; train and improve our workforce; strengthen partnerships among businesses, universities and community colleges, and government; and improve math and science K- education. New Jobs Across North Carolina should be carefully considered. I know that my administration and especially the Department of Commerce will take advantage of this report as we develop next steps in economic development strategy and determine how best to position North Carolina to gain the eco- nomic and social benefits from biotechnology. North Carolina should be on every company’s short list of places to carry out biotechnology research, development, testing, and manufacturing. Working together, I believe that we can and will achieve that goal. — Michael F. Easley Governor, State of North Carolina 2 3 New Jobs Across North Carolina A Strategic Plan for Growing the Economy Statewide through Biotechnology Steering Committee Mr. Dennis J. Dougherty e Honorable Beverly E. Perdue General Partner Lieutenant Governor Co-Chairs: Intersouth Partners State of North Carolina e Honorable James B. Hunt, Jr. Secretary James T. Fain III Ralph Snyderman, M.D. Womble Carlyle Sandridge & Rice, Secretary Chancellor, Health Affairs PLLC North Carolina Department of Duke University e Honorable James G. Martin Commerce e Honorable E. Norris Tolson Corporate Vice President Mr. Billy Ray Hall Secretary Carolinas HealthCare System President North Carolina Department of North Carolina Rural Economic Revenue Leslie M. Alexandre, Dr.P.H. Development Center, Inc. e Honorable William L. President and Chief Executive Charles E. Hamner, Ph.D., D.V.M. Wainwright Officer President Representative North Carolina Biotechnology North Carolina Biosciences North Carolina House of Center Organization Representatives Ms. Molly Corbett Broad Mr. Robert A. Ingram Mr. Richard L. Wiley President Vice Chairman, Pharmaceuticals Director, Economic Development e University of North Carolina GlaxoSmithKline Duke Power Mr. John F.A.V. Cecil e Honorable Martin Lancaster President President President North Carolina Economic Biltmore Farms, Inc. North Carolina Community College Development Association Mr. S. Lawrence Davenport System President e Honorable Howard N. Lee J.P. Davenport and Son, Inc. Chairman Mr. Walter Davis North Carolina State Board of Investor Education 2 3 New Jobs Across North Carolina Message from Gov. James B. Hunt and Gov. James G. Martin Co-Chairs, Strategic Plan Steering Committee When the North Carolina Biotechnology Center was created in , it was the first state-supported biotechnology initiative in the world. No other state or country has established such a comprehensive and effective model to stim- ulate biotechnology development. As a result, North Carolina has emerged as a leading place for biotechnology growth and development, creating jobs and improving our quality of life. Now, more than years later and with biotechnology growing at a more rapid pace than ever, we have put together a strategic plan to guide us through the next years, with the ultimate goal of having , biotechnology-related jobs by . To achieve this goal, we must get down to business fast by imple- menting the strategies in this plan. Strong cooperation among government, business, and academia is required to sustain the momentum that has put North Carolina among the nation’s top five biotechnology states. We must continue to recruit new companies, expand existing companies, and encour- age spinouts from companies and universities, and we must accelerate the pace at which we do so. We are fortunate in North Carolina to have the abil- ity to implement all of these efforts in all parts of the state. Biotechnology applications in North Carolina’s main industries — agriculture, health care, environmental sciences, forestry, and many others — are already spreading biotechnology beyond Research Triangle Park and into other areas of the state. North Carolina has all of the essential ingredients for success, including top-ranked universities and community colleges, a capable work force, and a high quality of life. We will continue to rely on these strengths to attract biotechnology companies to our state, but we must enhance them even fur- ther and be creative and innovative in meeting the competitive challenge. We already have a great foundation on which to build. We are at a competitive crossroads with many other states looking to recruit biotechnology companies. In this critical time, we must find the resources needed to implement this strategic plan effectively and efficiently to make sure that North Carolina is the most attractive state for companies looking to locate or expand. We have the potential to create thousands of new jobs in every part of North Carolina by applying these strategies. Ever since the Wright Brothers made their historic flight at Kitty Hawk in , North Carolina has been a leader in technology. One hundred years later, North Carolina is still cultivating that visionary spirit. As we celebrate being “First in Flight,” let us also strive to be first in biotechnology. — e Honorable James B. Hunt, Jr. — e Honorable James G. Martin Womble Carlyle Sandridge Corporate Vice President & Rice, PLLC Carolinas HealthCare System 4 5 New Jobs Across North Carolina Message from the President of the Biotechnology Center Six months ago, Governor Easley charged the Biotechnology Center with developing a long-term strategic plan to guide future state investments in biotechnology and appointed a blue-ribbon steering committee to help facili- tate our success. To ensure broad participation and diversity of views in the planning process, we promptly convened nearly North Carolinians repre- senting our many industrial, academic, governmental and community part- ners throughout the state. e result is New Jobs Across North Carolina: A Strategic Plan for Growing the Economy Statewide through Biotechnology. e plan’s stated goal of , and , biotechnology-related jobs in North Carolina by and respectively is clearly ambitious. To those of us familiar with North Carolina’s strong biotechnology assets, the goal is aggressive but fully achievable. Success, however, will depend on substantial and sustained investments in the strategies outlined in this plan and strong support from the parties involved with their implementation. Accounting for percent of all U.S. biotechnology jobs and revenue and with the fastest rate of growth of new companies in the country, North Carolina is already a leading site for biotechnology economic development. New Jobs Across North Carolina builds upon that success by leveraging the talents and resources of all participants in our large and cohesive biotechnology com- munity. e plan lays out an ambitious but realistic roadmap for moving the entire state forward in biotechnology development.
Load more

Recommended publications
  • Honoring Catalysts in Action Over the Winter and Spring Through Our Website, Facebook and Twitter
    8 CONNEC TCFS We have been honored to share the stories of 25 Catalysts Honoring Catalysts in Action over the winter and spring through our website, Facebook and Twitter. We hope you’ll take time to read about their remarkable lives and the courage and persistence they Throughout this issue of SolveCFS we pay tribute to the collective action demonstrate every day. As unique as each one is, they are united in their hope that research led by the CFIDS that has led up to the launch of the Association’s latest research initiative: Association of America will lead to better treatment and the research institute without walls (RIWW). Two individuals warrant spe - healthier futures. cial attention for their immensely important contributions. First, James York , the first person consented and enrolled to participate in the SolveCFS BioBank. James was working as an underwater camera man and marine coordinator in the film industry when pneumonia turned into CFS in 2004. He has turned to writing when cognitive impairment can be kept at bay, as a form of expression and, occasionally, compensation. James enrolled in the BioBank as soon as it was announced. He returned his signed consent James York, adrift and at work on the form promptly; completed the extensive medical award-winning film “Ocean Men: Extreme history questionnaire thoroughly and expeditiously Dive” with an IMAX Mark II camera and even recruited his own matched control to partici - housing in Stargate Cave on Andros Island pate. He gave blood samples and tissue swabs. He did in the Bahamas. The picture explored the so as part of an odyssey to learn about CFS and cope beauty and science of breath-hold diving with it.
    [Show full text]
  • Drug Delivery Technology Y
    * DDT Nov-Dec 2007 Working 11/9/07 2:29 PM Page 1 November/December 2007 Vol 7 No 10 IN THIS ISSUE Company Profiles 12 Drug Delivery Technologies 58 Excipients, Polymers, Liposomes & Lipids 78 Contract Pharmaceutical & Biological Development Services 83 Machinery & Laboratory Equipment and Software 96 Technology Showcase 102 The science & business of specialty pharma, biotechnology, and drug delivery www.drugdeliverytech.com * DDT Nov-Dec 2007 Working 11/9/07 2:39 PM Page 2 * DDT Nov-Dec 2007 Working 11/9/07 2:40 PM Page 3 * DDT Nov-Dec 2007 Working 11/9/07 2:40 PM Page 4 November/December 2007 Vol 7 No 10 PUBLISHER/PRESIDENT Ralph Vitaro EXECUTIVE EDITORIAL DIRECTOR Dan Marino, MSc [email protected] CREATIVE DIRECTOR Shalamar Q. Eagel CONTROLLER Debbie Carrillo CONTRIBUTING EDITORS Cindy H. Dubin Debra Bingham Jason McKinnie TECHNICAL OPERATIONS Mark Newland EDITORIAL SUPPORT Nicholas D. Vitaro ADMINISTRATIVE SUPPORT Kathleen Kenny Corporate/Editorial Office 219 Changebridge Road, Montville, NJ 07045 Tel: (973)299-1200 Fax: (973) 299-7937 www.drugdeliverytech.com Advertising Sales Offices East & Midwest Victoria Geis - Account Executive Coming in 2008 Cheryl S. Stratos - Account Executive 103 Oronoco Street, Suite 200 Alexandria, VA 22314 Tel: (703) 212-7735 Drug Delivery Weekly & Fax: (703) 548-3733 E-mail: [email protected] Specialty Pharma News E-mail: [email protected] West Coast Warren De Graff Western Regional Manager 818 5th Avenue, Suite 301 San Rafael, CA 94901 Tel: (415) 721-0644 Fax: (415) 721-0665 E-mail: [email protected] 0 The weekly electronic newsletter from the publishers of Drug 1 International o N Delivery Technology and Specialty Pharma will provide over 12,000 Ralph Vitaro 7 219 Changebridge Road l o subscribers with the latest news of business deals, alliances, and V Montville, NJ 07045 Tel: (973) 299-1200 7 technology breakthroughs from the pharmaceutical, specialty 0 Fax: (973) 299-7937 0 2 pharmaceutical, drug delivery, and biotechnology industries.
    [Show full text]
  • Progress Report January 2009 – December 2011
    North Carolina State University Professional Science Master’s Program Progress Report January 2009 – December 2011 The Graduate School College of Agriculture & Life Sciences College of Design College of Education College of Engineering College of Humanities & Social Sciences Poole College of Management College of Natural Resources College of Physical & Mathematical Sciences College of Textiles College of Veterinary Medicine First-Year College 1 Greetings From the UNC System PSM Director The Professional Science Master’s (PSM) Program is one of the University of North Carolina (UNC) System’s ways to close the existing skills gap in the workplace. Together with local employers, we design graduate education and training regimens to match employers’ needs. The UNC System has undertaken a collaborative effort to develop these new programs in key areas of importance to North Carolina’s local economies. I am pleased to report that NC State University now offers nine PSM programs. Several new programs are at various planning stages, and numerous new central resources and services are available or under way for these programs. A special milestone in 2010 was the establishment of the PSM Council at NC State University. Members of this group include faculty who direct PSM programs or are planning to offer them in the future. The PSM Council oversees new program development and determines the future strategy for the PSM programs at NC State University. Another important milestone was the award of a new UNC System grant from the Alfred P. Sloan Foundation and support from the UNC General Administration for multiple online tools. I am greatly indebted to the many employers, professors and students who contribute to the collective success of NC State University’s PSM programs.
    [Show full text]
  • PIIS0016508516348168(1).Pdf
    Gastroenterology 2016;151:651–659 CLINICAL—LIVER High Efficacy of ABT-493 and ABT-530 Treatment in Patients With HCV Genotype 1 or 3 Infection and Compensated Cirrhosis Edward Gane,1 Fred Poordad,2 Stanley Wang,3 Armen Asatryan,3 Paul Y. Kwo,4 Jacob Lalezari,5 David L. Wyles,6 Tarek Hassanein,7 Humberto Aguilar,8 Benedict Maliakkal,9 Ran Liu,3 Chih-Wei Lin,3 Teresa I. Ng,3 Jens Kort,3 and Federico J. Mensa3 1University of Auckland, Auckland, New Zealand; 2Texas Liver Institute, University of Texas Health Science Center, San Antonio, Texas; 3AbbVie, Inc, North Chicago, Illinois; 4Indiana University School of Medicine, Indianapolis, Indiana; 5Quest Clinical Research, San Francisco, California; 6University of California San Diego, La Jolla, California; 7Southern California GI and Liver Centers and Southern California Research Center, Coronado, California; 8Louisiana Research Center, Shreveport, Louisiana; 9University of Rochester Medical Center, Rochester, New York to liver decompensation, as defined by ascites, jaundice, See Covering the Cover synopsis on page 571; encephalopathy, or variceal bleeding.2 Achievement of a CLINICAL LIVER see editorial on page 587. sustained virologic response (SVR) reduces the risk of hepatic decompensation events, end-stage liver disease, 3–5 BACKGROUND & AIMS: The combination of ABT-493 (NS3/4A hepatocellular carcinoma, and liver-related mortality. protease inhibitor) plus ABT-530 (NS5A inhibitor) has shown Recognizing the need to prevent these complications, the high rates of sustained virologic response at post-treatment American Association for the study of Liver Diseases/ week 12 (SVR12) in noncirrhotic patients infected with hepa- Infectious Disease Society of America, and the European titis C virus (HCV) genotypes (GTs) 1–6.
    [Show full text]
  • Radius Health, Inc
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material Pursuant to §240.14a-12 RADIUS HEALTH, INC. (Name of Registrant as Specified in its Charter) (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant) Payment of Filing Fee (Check the appropriate box): ☒ No fee required. ☐ Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. (1) Title of each class of securities to which transaction applies: (2) Aggregate number of securities to which transaction applies: (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): (4) Proposed maximum aggregate value of transaction: (5) Total fee paid: ☐ Fee paid previously with preliminary materials: ☐ Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. (1) Amount previously paid: (2) Form, Schedule or Registration Statement No.: (3) Filing Party: (4) Date Filed: April 20, 2018 To Our Stockholders: You are cordially invited to attend the 2018 Annual Meeting of Stockholders of Radius Health, Inc.
    [Show full text]
  • 4Oct200722045121 1Dec200517045043
    4OCT200722045121 This prospectus (the ‘‘Prospectus’’) relates to the initial offering (the ‘‘Offering’’) to subscribe for up to A75 million of new common shares in Ablynx NV (the ‘‘Company’’ or ‘‘Ablynx’’), with VVPR strips (the ‘‘VVPR Strips’’). This amount of New Shares with VVPR Strips may be increased by up to 15 per cent, to an amount of A86.25 million (the ‘‘Increase Option’’, the new shares initially offered and the shares offered as a result of the possible exercise of the Increase Option jointly being referred to as the ‘‘New Shares’’). Any decision to exercise the Increase Option will be announced, at the latest, on the date the Offer Price is announced. JPMorgan and KBC Securities (the ‘‘Joint Global Coordinators’’) will be granted an over-allotment option by the Company (the ‘‘Over-allotment Option’’), exercisable as of the listing date (the ‘‘Listing Date’’) and until 30 days thereafter, corresponding to up to 15 per cent of the New Shares subscribed for in the Offering for the sole purpose of allowing the Joint Global Coordinators to cover over-allotments, if any. The existing shares covered by the Over-allotment Option (the ‘‘Additional Shares’’ and, together with the New Shares, the ‘‘Offered Shares’’) and the New Shares issued upon exercise of the Over-allotment Option, if any, will not have a separate VVPR Strip. The Offered Shares are offered to the public in Belgium (including to employees, consultants and independent directors of the Company in Belgium) and, pursuant to a private placement, to institutional investors, both within and outside Belgium and to employees, consultants and independent directors of the Company outside Belgium.
    [Show full text]
  • Life Sciences Industry Wake County * Research Triangle Index of Featured Organizations Contract Research Contract Manufacturer 48
    LIFE SCIENCES INDUSTRY WAKE COUNTY * RESEARCH TRIANGLE INDEX OF FEATURED ORGANIZATIONS Contract Research Contract Manufacturer 48. Kurve Technology, Inc. ...............................D4 49. LaamScience, Inc. ...............................C4, I10 1. A10 Clinical Solutions, Inc. ........................E5 71. Accurate Machine and Tool Co. .................E8 50. LipoScience, Inc. ........................................C7 2. AAIPharma, Inc....................................C4, I11 72. Better Medicines, LLC ................................C3 51. Mardil, Inc. ..................................................D4 3. Alpha-Gamma Technologies, Inc. ..............D7 73. Merck BioManufacturing Network .............D4 52. MDxHealth, Inc. ................................... B3, G9 4. Analytical Solutions, Inc. ..................... C3, H9 74. Nortech Systems 53. Med-El Corp. ..................................... B3, G10 5. Appealing Products, Inc. ............................E6 (Formally TriVirix International) ..................A3 54. MedFaxx, Inc. .............................................A8 6. BIoCI Systems, Inc. ....................................D8 75. Patheon, Inc. .......................................C4, I11 55. Medisim USA .............................................. F5 7. BioLink Life Sciences, Inc. .........................D4 76. Rockwell Automation Life Sciences ...........E4 56. Medis Medical Imaging Systems, Inc. ........C7 8. Burleson Research Technologies ..............C4 77. Stainless Steel Fabrications .......................D7
    [Show full text]
  • AMERICAN HELLENIC CHAMBER of COMMERCE Amcham.Gr
    2018-11-15_ASPROFOS_ADS_01_outline.pdf 1 15/11/2018 7:28:55 μμ C M Y CM MY CY CMY K AMERICANHELLENIC CHAMBER OF C OMMERCE amcham.gr KTX Directory AmCham fin.indd 1 9/11/2018 1:37:03 μμ .PRESS Integrated kitchen & bathroom solutions CHAMBER 60 years of expertise European manufacturing footprint Global presence in 65 countries PYRAMIS METALLOURGIA Α.Ε. 17th km Thessaloniki - Serres | P.O. Box 10 278 | 54110, Thessaloniki, Greece follow us @PyramisGroup Τel.: +30 23940 56700 | Fax.: +30 23940 71134 | [email protected] | www.pyramisgroup.com .PRESS Integrated kitchen & bathroom solutions CHAMBER 60 years of expertise European manufacturing footprint Global presence in 65 countries PYRAMIS METALLOURGIA Α.Ε. 17th km Thessaloniki - Serres | P.O. Box 10 278 | 54110, Thessaloniki, Greece follow us @PyramisGroup Τel.: +30 23940 56700 | Fax.: +30 23940 71134 | [email protected] | www.pyramisgroup.com 2018-11-15_ASPROFOS_ADS_01_outline.pdf 1 15/11/2018 7:28:55 μμ C M Y CM MY CY CMY K AMERICANHELLENIC CHAMBER OF C OMMERCE amcham.gr KTX Directory AmCham fin.indd 1 9/11/2018 1:37:03 μμ DIRECTORY 2019 AMERICANHELLENIC CHAMBER OF COMMERCE amcham.gr KTX_SPENDEO_20,8x28_Final.pdf 1 16/11/18 11:14 π.µ. 2 | DIRECTORY 2019 KTX_SPENDEO_20,8x28_Final.pdf 1 16/11/18 11:14 π.µ. contents U.S. PAGES 105 The United States Government in Greece ..... 106 The Commercial Service U.S. Embassy Athens...................... 108 U.S. Government Agencies and Offices ...... 110 Business and Professional Organizations in the United States ....................... 112 American Chambers of Commerce CHAMBER PAGES 17 in Europe ...............................
    [Show full text]
  • Download the Pdf Here
    Address correspondence to: Early Clearance of HCV RNA in HCV Genotype 1 Treatment-naïve Patients Treated with Telaprevir, Peginterferon and Ribavirin: Kenneth E. Sherman, MD, PhD. 957 Division of Digestive Diseases, University of Pooled Analysis of the Phase 3 Trials ADVANCE and ILLUMINATE Cincinnati College of Medicine, Cincinnati, OH KE Sherman1, GT Everson2, IM Jacobson3, AM Di Bisceglie4, DR Nelson5, L Bengtsson6, N Adda6, RS Kauffman6, CI Wright6, and S Zeuzem7 Email: [email protected] 1University of Cincinnati College of Medicine, Cincinnati, OH, USA; 2University of Colorado Denver, Aurora, CO, USA; 3Weill Cornell Medical College, New York, NY, USA; 4Saint Louis University School of Medicine, Saint Louis, MO, USA; 5University of Florida, Gainesville, FL, USA; 6Vertex Pharmaceuticals Incorporated, Cambridge, MA, USA; 7Johann Wolfgang Goethe University Medical Center, Frankfurt am Main, Germany. Patient Population ABSTRACT Figure 2: Patients with Undetectable HCV RNA over Time Figure 5: Patients who Achieved SVR According to Week 1, Week 2, or Week 4 SUMMARY AND CONCLUSIONS • Treatment-naïve patients infected with genotype 1 chronic HCV were enrolled: HCV RNA Undetectability • Background: Phase 3 trials have demonstrated that addition of telaprevir to currently approved regimens containing – 123 centers in North America, Europe, Argentina, Australia and Israel in ADVANCE peginterferon alfa and ribavirin significantly increased treatment response rates and permitted the majority of patients (A) (B) • More patients were undetectable for HCV RNA at early timepoints (pts) to shorten treatment duration to 24 wks. – 74 centers in the United States and Europe in ILLUMINATE Week 1 Undetectable Week 2 Undetectable Week 4 Undetectable 100 100 when treated with a telaprevir-based regimen.
    [Show full text]
  • Molecular Medicine Tri-Conference
    Register by January 15 and SAVE up to $200 Premier Sponsors Corporate Sponsors Conference: February 3-5 | Exhibits: February 3-4 Moscone North Convention Center | San Francisco, CA PLENARY KEYNOTES When Drug Research is Personal John F. Crowley, Founder, Novazyme Pharmaceuti cals, Inc. Technology, Aging, and the Brain Biotechnologies GmbH ® Gary W. Small, M.D., Professor, Meso Scale Discovery David Geff en School of Medicine, University of California, Los Angeles Chips, Clones and Living Beyond 100 Paul J.H. Schoemaker, Ph.D., Lead Sponsoring Publicati ons M.B.A., Professor, Wharton School of Business Corporate Support Sponsors Co - Sponsors The State of California Cambridge Healthtech Institute • 250 First Avenue, Suite 300, Needham, MA 02494 Telephone: 781-972-5400 or Toll-Free in the U.S. 888-999-6288 • Fax: 781-972-5425 Tri-Conference.com Media Partners CONFERENCE-AT-A-GLANCE Tuesday, February 2 The Open Access Publisher 8:00 AM Morning Short Course Registration and Coffee 9:00 - 12:00 PM Morning Short Courses (Courses 1-6) 10:15 - 10:30 Networking Coffee Break 1:00 - 2:00 Afternoon Short Course Registration 2:00 - 5:00 Afternoon Short Courses (Courses 7-12) 3:15 - 3:30 Networking Refreshment Break 5:00 Close of Day Wednesday, February 3 7:00 AM Registration and Morning Coffee 8:00 - 9:40 Plenary Keynotes 9:40 - 11:00 Grand Opening Refreshment Break in the Exhibit Hall Nanomedicine 11:00 - 12:40 PM Concurrent Channels 12:40 - 1:45 Sponsored Luncheon Presentations or Lunch on Your Own 1:45 - 2:15 Dessert in the Exhibit Hall 2:15 - 4:20
    [Show full text]
  • The Intellectual Property, Licensing, and Business Development Event of the Year
    CLP & CPEEarn Credit CLE, OCTOBER 14 –17 Sheraton Centre Toronto Toronto, ON, Canada The Intellectual Property, Licensing, and Business Development Event of the Year FEATURING THESE CUTTING-EDGE TOPICS: Connecting & Collaborating: The Convergence of Life Sciences and High Tech Carving Out Your Commercial Space — Strategies and Trade Offs Is High Tech Crazy? Are We Experiencing a Patent Bubble? Benches Unleashed: Judicial Views on Fixing the Systems The Role of IP in Rebuilding Economies Following the Arab Spring How Outcomes of Patent Fights have Changed the Course of History REGISTER BY JULY 31 & SAVE $200! www.LE S2012.org WHO SHOULD ATTEND: Don’t Miss Your Opportunity Professionals to Connect and Collaborate involved with: Business Join more than 1,000 of your colleagues for the LES 2012 Annual Meeting, Development October 14 –17 in Toronto. Intellectual Property The LES Annual Meeting is the must-attend IP, licensing, and business development event Investments of the year — featuring 3½ days of high-quality educational sessions, ample networking Legal opportunities and the industry’s leading Tech Fair. Licensing Open Innovation Fuel Your Network Technology Transfer The LES Annual Meeting provides ample opportunities to connect with your colleagues. R&D Various events, including receptions, breakfasts, lunches and breaks, will allow you to discuss your day-to-day challenges and unique issues with other licensing professionals from around the world. You’re sure to learn tips, tactics and strategies that you can apply From the following back at your workplace. industries: Biotechnology Chemicals & Discover New Resources and Solutions Materials The LES Annual Meeting Tech Fair on October 16 is a vital extension of the educational program and represents a valuable opportunity to cultivate resources that will help you Consumer Products and your organization stay ahead of the competition.
    [Show full text]
  • Adult Major Depressive Disorder (Mdd) Treatment Tool Box
    ADULT MAJOR DEPRESSIVE DISORDER (MDD) TREATMENT TOOL BOX This activity is jointly sponsored/co-provided by This activity is supported by an educational grant from ADULT MDD TREATMENT TOOL BOX Release date: October 13, 2011 • Implement a system-wide approach to collaborative care, Expiration date: April 30, 2013 stepped care, and medication therapy management Estimated time to complete activity: 1.0 hours • Implement patient screening and monitoring that leverages health information technology advances to improve outcomes for adult Intended Audience patients with MDD This activity has been designed to meet the educational needs of: • Provide appropriate care and counsel for patients and their • Psychiatrists, primary care physicians, and other clinicians families involved with the care of adult patients with major depressive • Provide accurate and appropriate counsel as part of the disorder treatment team • Medical Directors and Pharmacy Directors from health plans, HMOs, integrated health systems, employers, quality organizations, Physician Continuing Medical Education public payer groups, and other managed care organizations and health insurers Accreditation Statement This activity has been planned and implemented in accordance • Managed care affiliated care team members involved with patient with the Essential Areas and policies of the Accreditation Council evaluation, education, and follow-up for adult patients with MDD for Continuing Medical Education through the joint sponsorship of including: physicians, pharmacists, registered nurses, and care Postgraduate Institute for Medicine and Impact Education, LLC. managers Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians. Statement of Educational Need Credit Designation Statement Adult MDD is a serious medical illness affecting 15 million American The Postgraduate Institute for Medicine designates this enduring adults, or approximately 5-8% of the adult population in a given year.
    [Show full text]